Amtagvi

FDA Approves Amtagvi, First Cell Therapy for Melanoma, Developed by Iovance Biotherapeutics

by

San Carlos, California – The FDA has given approval to a revolutionary cancer treatment called Amtagvi, developed by Iovance Biotherapeutics. This cell therapy aims to address aggressive forms of melanoma, a type of skin cancer. Amtagvi is intended for patients whose melanoma cannot be surgically removed or has metastasized to other parts of the body. The treatment involves the extraction and replication of T cells obtained from the patient’s tumor. These T cells, which are …

Read more

Game Changing FDA Approval for Cancer Immunotherapy Lifileucel After 40 Years: Amtagvi Receives Accelerated FDA Approval for Advanced Melanoma

by

LOS ANGELES, California – After nearly four decades since its inception, the first TIL therapy has received accelerated approval from the Food and Drug Administration for advanced melanoma. This immunotherapy, which harvests cancer-fighting immune cells from the patient’s own body, is called Amtagvi or lifileucel from Iovance, and is the first cell therapy approved for a solid tumor. Allison Betof Warner, a cell therapy researcher and physician at Stanford University, expressed her excitement and gratification, …

Read more